Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107456418> ?p ?o ?g. }
- W2107456418 endingPage "215" @default.
- W2107456418 startingPage "215" @default.
- W2107456418 abstract "Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis Rafael Gálvez1, Victoria Ribera2, José Ramón González-Escalada3, Alicia Souto4, María Luz Cánovas4, Andrés Castro4, Begoña Herrero5, María de los Ángeles Maqueda5, Matilde Castilforte6, José Javier Marco-Martínez7, Concepción Pérez8, Lorenza Vicente-Fatela9, Consuelo Nieto MD10, Maria José Orduña11, Anna Padrol12, Enrique Reig13, Joaquín Carballido14, José Manuel Cózar151Pain and Palliative Care Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain; 2Pain Unit, Hospital Vall d’Hebron, Barcelona, Spain; 3Pain Unit, Hospital Ramón y Cajal, Madrid, Spain; 4Pain Unit, Hospital Cristal Piñor, Ourense, Spain; 5Pain Unit, Hospital Virgen de la Macarena, Sevilla, Spain; 6Pain Unit, Fundación Jiménez Díaz, Madrid, Spain; 7Pain Unit, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain; 8Pain Unit, Hospital La Princesa, Madrid, Spain; 9Pain Unit, Hospital Universitario 12 de Octubre, Madrid, Spain; 10Pain Unit, Fundación Alcorcón, Madrid, Spain; 11Pain Unit, Hospital Xeral-Calde, Lugo, Spain; 12Pain Unit, Hospital Joan XXIII, Tarragona, Spain; 13Pain Unit, Hospital Puerta del Hierro, Madrid, Spain; 14Urology Service, Hospital Puerta del Hierro, Madrid, Spain; 15Urology Service, Hospital Universitario Virgen de las Nieves, Granada, SpainObjectives: A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis.Materials and Methods: Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluated were: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance and treatment satisfaction were assessed using a questionnaire.Results: A total of 170 that matched all the inclusion criteria (78%) out of 218 were evaluable for efficacy. There was a measurable statistically significant reduction in pain at rest and on movement as well as an improvement in the quality of life compared with baseline. Best results were obtained with early treatment. Overall incidence of bone events was 11.2%. Of the 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatmentDiscussion: Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis. Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the management of patients with pain associated with bone metastasis from prostate cancer.Keywords: bone metastasis, pain, prostate cancer, zoledronic acid" @default.
- W2107456418 created "2016-06-24" @default.
- W2107456418 creator A5002457309 @default.
- W2107456418 creator A5006036574 @default.
- W2107456418 creator A5010895253 @default.
- W2107456418 creator A5013146389 @default.
- W2107456418 creator A5016554782 @default.
- W2107456418 creator A5021640954 @default.
- W2107456418 creator A5026967961 @default.
- W2107456418 creator A5031135111 @default.
- W2107456418 creator A5041960706 @default.
- W2107456418 creator A5044266522 @default.
- W2107456418 creator A5045373380 @default.
- W2107456418 creator A5048134692 @default.
- W2107456418 creator A5054714700 @default.
- W2107456418 creator A5059073275 @default.
- W2107456418 creator A5059764449 @default.
- W2107456418 creator A5068468054 @default.
- W2107456418 creator A5083524090 @default.
- W2107456418 creator A5089860710 @default.
- W2107456418 date "2008-08-01" @default.
- W2107456418 modified "2023-09-27" @default.
- W2107456418 title "Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis" @default.
- W2107456418 cites W1513170608 @default.
- W2107456418 cites W1517801548 @default.
- W2107456418 cites W1938796902 @default.
- W2107456418 cites W1973945362 @default.
- W2107456418 cites W1974305754 @default.
- W2107456418 cites W1977823327 @default.
- W2107456418 cites W1989587278 @default.
- W2107456418 cites W1993669370 @default.
- W2107456418 cites W1993701679 @default.
- W2107456418 cites W2024266959 @default.
- W2107456418 cites W2026455376 @default.
- W2107456418 cites W2027735110 @default.
- W2107456418 cites W2033885211 @default.
- W2107456418 cites W2040878961 @default.
- W2107456418 cites W2041095267 @default.
- W2107456418 cites W2052104719 @default.
- W2107456418 cites W2060736857 @default.
- W2107456418 cites W2065444789 @default.
- W2107456418 cites W2093871127 @default.
- W2107456418 cites W2104923745 @default.
- W2107456418 cites W2130934441 @default.
- W2107456418 cites W2141046618 @default.
- W2107456418 cites W2161962336 @default.
- W2107456418 cites W2315465903 @default.
- W2107456418 cites W2326495145 @default.
- W2107456418 cites W2330096705 @default.
- W2107456418 cites W2401840478 @default.
- W2107456418 cites W2409621768 @default.
- W2107456418 cites W2417835951 @default.
- W2107456418 cites W2433021383 @default.
- W2107456418 cites W2607028219 @default.
- W2107456418 doi "https://doi.org/10.2147/ppa.s2314" @default.
- W2107456418 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2770417" @default.
- W2107456418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19920966" @default.
- W2107456418 hasPublicationYear "2008" @default.
- W2107456418 type Work @default.
- W2107456418 sameAs 2107456418 @default.
- W2107456418 citedByCount "8" @default.
- W2107456418 countsByYear W21074564182012 @default.
- W2107456418 countsByYear W21074564182013 @default.
- W2107456418 countsByYear W21074564182014 @default.
- W2107456418 countsByYear W21074564182017 @default.
- W2107456418 countsByYear W21074564182020 @default.
- W2107456418 crossrefType "journal-article" @default.
- W2107456418 hasAuthorship W2107456418A5002457309 @default.
- W2107456418 hasAuthorship W2107456418A5006036574 @default.
- W2107456418 hasAuthorship W2107456418A5010895253 @default.
- W2107456418 hasAuthorship W2107456418A5013146389 @default.
- W2107456418 hasAuthorship W2107456418A5016554782 @default.
- W2107456418 hasAuthorship W2107456418A5021640954 @default.
- W2107456418 hasAuthorship W2107456418A5026967961 @default.
- W2107456418 hasAuthorship W2107456418A5031135111 @default.
- W2107456418 hasAuthorship W2107456418A5041960706 @default.
- W2107456418 hasAuthorship W2107456418A5044266522 @default.
- W2107456418 hasAuthorship W2107456418A5045373380 @default.
- W2107456418 hasAuthorship W2107456418A5048134692 @default.
- W2107456418 hasAuthorship W2107456418A5054714700 @default.
- W2107456418 hasAuthorship W2107456418A5059073275 @default.
- W2107456418 hasAuthorship W2107456418A5059764449 @default.
- W2107456418 hasAuthorship W2107456418A5068468054 @default.
- W2107456418 hasAuthorship W2107456418A5083524090 @default.
- W2107456418 hasAuthorship W2107456418A5089860710 @default.
- W2107456418 hasBestOaLocation W21074564181 @default.
- W2107456418 hasConcept C121608353 @default.
- W2107456418 hasConcept C122637931 @default.
- W2107456418 hasConcept C126322002 @default.
- W2107456418 hasConcept C145420912 @default.
- W2107456418 hasConcept C187212893 @default.
- W2107456418 hasConcept C2776326535 @default.
- W2107456418 hasConcept C2777783956 @default.
- W2107456418 hasConcept C2779013556 @default.
- W2107456418 hasConcept C2992019943 @default.
- W2107456418 hasConcept C3017595490 @default.
- W2107456418 hasConcept C33923547 @default.
- W2107456418 hasConcept C71924100 @default.